Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bravida in connection with the listing of its SEK Senior Secured Floating Rate Notes on NASDAQ OMX Stockholm
Mandate

Vinge advises Bravida in connection with the listing of its SEK Senior Secured Floating Rate Notes on NASDAQ OMX Stockholm

December 20, 2013

Vinge has assisted Bravida Holding AB (publ) in connection with the admission to trading of its SEK 1.3 billion aggregate principal amount senior secured floating rate notes on the regulated market of NASDAQ OMX Stockholm. The senior secured floating rate notes were issued on 11 June 2013 and are also listed on the MTF Global Exchange Market (GEM) of the Irish Stock Exchange. The dual listing on NASDAQ OMX Stockholm entails that the notes can now also be traded on a regulated market.

Bravida is Scandinavia’s premier integrated supplier of technical installation and service solutions, with nearly 8,000 employees. Bravida offers specialist expertise and integrated solutions in electrical installations, heating & plumbing and HVAC and operates at all stages of the installation – from advice and project planning to installation and service. Bravida has offices at 150 locations in Sweden, Norway and Denmark.

Vinge’s team consisted of Peter Bäärnhielm, Dain Nevonen and Oskar Belani. Christina Kokko is client responsible partner.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025